Lenacapavir, a treatment administered subcutaneously every six months, is capable of preventing infection with very high ...

That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...

The development of the HIV infection-preventing drug lenacapavir is the most important research development of 2024, Science ...

The drug lenacapavir, developed by Gilead Sciences, provides protection for half a year instead of one day and has performed extremely well in clinical trials.

Breakthrough of The Year, Science has named the development of lenacapavir – a promising new injectable drug that prevents HIV infection. The award also recognizes related work surrounding gaining a ...

The US journal "Science" has named the development of the drug Lenacapavir as this year's "Breakthrough of the Year". The ...

Deaths from HIV/AIDS are ten times lower than at the peak of the epidemic, and new research could drive that down even more.

Conducted by Emory University and Grady Health System and funded by Gilead, the trial showed that Lenacapavir offers a ...

Musk has argued in favor of regulating AI. But venture capitalists like Andreessen, who founded Andreessen Horowitz, a VC ...

LOS ANGELES, Dec. 13 (Xinhua) -- An injectable HIV drug with novel mechanism was named on Thursday by the influential U.S. journal "Science" as Breakthrough of the Year. The drug, named lenacapavir, ...

Want to stay on top of the science and politics driving biotech today ... The drug is another formulation of lenacapavir, a ...

Drugmaker Gilead said it will allow cheap, generic versions to be sold in 120 poor countries with high HIV rates, mostly in ...